Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis

Bilateral Primary Osteoarthritis of Knee Clinical Trial

— BMAC  

Official title:

Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis, A Randomized Placebo Controlled Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01931007
• Other study ID #: 12-004459
• Status: Completed
• Phase: Phase 1
• First received: August 26, 2013
• Last updated: May 3, 2017
• Start date: August 2013
• Est. completion date: January 2016

Study information

• Verified date: May 2017
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall goal of this study is to develop regenerative cell therapy for use in patients with osteoarthritis (OA). The primary objective of this proposal is to conduct a pilot study that assesses the safety and feasibility of using concentrated bone marrow aspirate containing MSC to treat patients with painful knee OA.

Description:

Patients with symptomatic mild to moderate bilateral knee osteoarthritis will be candidates for this pilot study. Baseline data includes radiographs, MRI imaging, clinical data on knee pain and analysis of synovial fluid inflammatory markers. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the bone marrow concentrate. The contralateral knee will be injected with only sterile saline for placebo. Follow-up analysis of synovial fluid will be at one week and 6 months after injection; clinical data will be obtained at 3, 6 and 12 months and MRI imaging will be performed at 6 months after injection, with repeat radiographs at 12 months

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: January 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

1. Male and Female subjects are both eligible

2. Subjects must be 18 years of age or older

3. Subjects must have bilateral OA and pain in both knees.

4. Osteoarthritis may be primary or secondary. Knees must have Kellgren-Lawrence Grades 1-3.

5. Subjects must have previously tried 6 weeks of one of the following conservative treatments Activity modification, weight loss; physical therapy, anti-inflammatory or injection therapy

6. Patients can provide written informed consent after the nature of the study is fully explained

Exclusion Criteria:

1. Patients with abnormal hematology, serum chemistry, or urinalysis screening laboratory results.

2. Patients taking anti-inflammatory medications (prescription or over-the-counter), including herbal therapies, within 14 days of baseline visit.

3. Patients taking anti-rheumatic disease medication (including methotrexate or other antimetabolites) within the 3 months prior to study entry.

4. Patients receiving injections to the treated knee within 2 months prior to study entry.

5. Patients who are pregnant or currently breast-feeding children.

6. Patients with systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and synovial chondromatosis.

7. Patients with ongoing infectious disease, including HIV and hepatitis

8. Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer, or diabetes

9. Patients participating in a study of an experimental drug or medical device within 30 days of study entry.

Related Conditions & MeSH terms

• Bilateral Primary Osteoarthritis of Knee
• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Drug:
• Autologous Bone Marrow Aspirate Concentrate
Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.
• Sterile saline
Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.

Locations

Country	Name	City	State
United States	Mayo Clinic Jacksonville	Jacksonville	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

References & Publications (1)

Shapiro SA, Kazmerchak SE, Heckman MG, Zubair AC, O'Connor MI. A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis. Am J Sports Med. 2017 Jan;45(1):82-90. doi: 10.1177/0363546516662455. Epub 20 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects with Adverse Reactions to Concentrated Mesenchymal Stem Cells (MSCs)	Occurrence of adverse reactions to concentrated MSCs from bone marrow aspiration injected into knee joints.	1 year
Secondary	Mean Knee Cartilage	Knee cartilage status will be measured prior to injection, at 6 months following injection, and at 12 months following injection. The cartilage will be measured by MRI at baseline and 6 months using MRI and cartilage sequencing techniques, and knee radiographs at 12 months.	baseline, 6 months, 1 year